ZA 66 125 mg
Pill imprint ZA 66 125 mg has been identified as Divalproex sodium (sprinkle) 125 mg.
Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; epilepsy; hyperekplexia and belongs to the drug class fatty acid derivative anticonvulsants. There is positive evidence of human fetal risk during pregnancy.
Divalproex sodium 125 mg is not subject to the Controlled Substances Act.
See also related documents.
Divalproex sodium (sprinkle) Images
- Imprint:
-
ZA 66
125 mg - Strength:
- 125 mg
- Color:
- Blue & White
- Size:
- 22.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Inactive Ingredients:
- silicon dioxide colloidal
FD&C Blue No. 1
gelatin
hypromellose
sodium lauryl sulfate
magnesium silicate
titanium dioxide
triethyl citrate
- Drug Class:
- Fatty acid derivative anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Zydus Pharmaceuticals
- National Drug Code (NDC):
- 68382-0106
| NDC Code | Manufacturer / Repackager |
|---|---|
| 68084-0313 | Amerisource Health Services |
Note: Inactive ingredients may vary.
Advertisement
More Divalproex Sodium (Sprinkle) resources
- Divalproex Delayed-Release Tablets (Wolters Kluwer)
- Divalproex Extended-Release Tablets (Wolters Kluwer)
- Divalproex Sprinkle Capsules (Wolters Kluwer)
- divalproex sodium (Cerner Multum)
- Alti-Valproic (Micromedex) - Includes Dosage Information
- Depakote DR (Micromedex) - Includes Dosage Information
- divalproex sodium (Micromedex) - Includes Dosage Information
- Depakote Pellets (FDA)
- Divalproex (FDA)
- Divalproex Capsules (FDA)
- Divalproex Delayed Release (FDA)
- Divalproex Extended Release (FDA)
- Divalproex Sprinkle (FDA)
Search Again
